RxDoctor Payments Data

Joseph Aleshaki, DO

Dermatology · Santee, CANPI 1548766264

Payments from drug & device makers

$3,793in general payments, 2019–2025

Across 182 payments — averaging $20.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$648
  • Johnson & Johnson$522
  • Incyte Corporation$511
  • UCB, Inc.$282
  • AbbVie$272
  • Pfizer$235
  • plus $1K from 13 others

What the payments were for

  • Food & beverage$3,33488%
  • Education$45912%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,793 in reported general payments places this provider in the 60th percentile of 1,875 dermatology providers in California.

See all dermatology providers in California

Medicare billing

Part B allowed, 2024
$149,905
Medicare patients
375
Services billed
2,029

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OpzeluraRuxolitinib Phosphate11$22,263
Fluorouracil105$10,623
Tacrolimus19$2,403
Hydroxychloroquine Sulfate39$2,128
Clobetasol Propionate34$1,696
Ketoconazole114$1,630
Fluocinonide30$1,218
Betamethasone Dipropionate20$1,069
Ciclopirox23$1,038
Metronidazole13$869
Triamcinolone Acetonide90$834
Doxycycline Monohydrate33$782
Hydrocortisone105$747
Clindamycin Phosphate13$599
Mupirocin15$138

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationOpzelura$511$22,26311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,875 dermatology providers in California.

Other dermatology in Santee

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →